Ground substance

Nanalysis Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, April 29, 2024
International, Depreciation, Airport, Depression, Interest, Artificial intelligence, NMR, Artificiality, Ground substance, International Financial Reporting Standards, Detection, Nuclear magnetic resonance, NRC, Security, Bank statement, Growth, Hertz, Q&A

Gross margin percentage on product sales was 41% for the twelve months ended December 31, 2023, down from 49% in the prior year.

Key Points: 
  • Gross margin percentage on product sales was 41% for the twelve months ended December 31, 2023, down from 49% in the prior year.
  • Because of these cost-cutting measures, as well as improved sales markets, gross margin percentage on product sales rose to 48% in the fourth quarter.
  • Services gross margin percentage was (23%) for the twelve months ended December 31, 2023.
  • EBITDA loss for the twelve months ended December 31, 2023, was $8,074K versus an EBITDA loss of $3,935K in the same period last year.

Constellation Brands Announces Conversion of Common Shares and Exchange of Promissory Note Into Exchangeable Shares of Canopy Growth Corporation

Retrieved on: 
Thursday, April 18, 2024
Constellation, Controlled Substances Act, Indian stock exchange, Sale, Common, Ground substance, Note, Canopy Growth, Amendment, Conversion, Transaction, Constellation Brands, CBG, Security (finance)

VICTOR, N.Y., April 18, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that its indirect, wholly-owned subsidiaries, Greenstar Canada Investment Limited Partnership (“Greenstar”) and CBG Holdings LLC (“CBG”), have converted (the "Conversion”) their common shares (“Common Shares”) of Canopy Growth Corporation (“Canopy”) into non-voting and non-participating exchangeable shares of Canopy (“Exchangeable Shares”).

Key Points: 
  • VICTOR, N.Y., April 18, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that its indirect, wholly-owned subsidiaries, Greenstar Canada Investment Limited Partnership (“Greenstar”) and CBG Holdings LLC (“CBG”), have converted (the "Conversion”) their common shares (“Common Shares”) of Canopy Growth Corporation (“Canopy”) into non-voting and non-participating exchangeable shares of Canopy (“Exchangeable Shares”).
  • Greenstar and Canopy also agreed to exchange (the “Note Exchange” and together with the Conversion, the “Transactions”) C$81.2 million of the principal amount of the C$100 million promissory note due December 2024 issued by Canopy (the “Note”) for Exchangeable Shares pursuant to an exchange agreement between Greenstar and Canopy (the “Exchange Agreement”).
  • For early warning reporting purposes, Constellation will be deemed to beneficially own the Common Shares issuable on conversion of the Exchangeable Shares.
  • Based on the assumptions noted above and assuming no further issuances of Common Shares or Exchangeable Shares, if Constellation were to convert all such Exchangeable Shares into Common Shares it would hold an aggregate of 26,261,474 Common Shares (representing approximately 26.2% of the currently issued and outstanding Common Shares, inclusive of the as-converted Exchangeable Shares).

Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)

Retrieved on: 
Monday, April 15, 2024
Ground substance, Good manufacturing practice, Psychedelic drug, Drug development, MDP2P, Health Canada, Conference, API, MDMA, Science, Tel Aviv University, EST, Good, GMP, FRA, Fine chemical

VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.

Key Points: 
  • VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.
  • As previously communicated in January , Optimi employed the precursor 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) to guarantee the quality and uniformity of the MDMA API manufacturing process.
  • The production of this MDMA API was produced in-house, explicitly for the recently disclosed supply agreement with the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel.
  • Bill Ciprick, CEO of Optimi, confirms that the MDMA was tested and validated by a third-party laboratory, therefore meeting the Company’s quality assurance standards.

Indie Games Burst Onto Nintendo Switch Promising Adventure, Cozy Vibes, and Curious Cat Mischief

Retrieved on: 
Wednesday, April 17, 2024
Technology, Electronic Games, Entertainment, Online, Mobile Entertainment, Software, General Entertainment, Hardware, Consumer Electronics, Licensing (Entertainment), Lykke, Personality, Foot Clan, Destiny, Publishing, Assemble, Ground substance, Zee, Vainglory (video game), Travel, SteamWorld, Cat Quest, Future Friends, News, Sayonara Wild Hearts, Annapurna Interactive, Animal, Series, Hand, Weapon, Teenage Mutant Ninja Turtles, Moon, WayForward, Personality test, PLAYISM, ANIMAL, Foot, Nintendo Direct, Nintendo eShop, Light, Atari, Multimedia, Internet access, Indie, Nintendo Switch, SteamWorld Heist, Zephyr, Friends, DLC, Nintendo Switch Online, Video game

View the full release here: https://www.businesswire.com/news/home/20240417156103/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240417156103/en/
    Little Kitty, Big City releases on Nintendo Switch on May 9.
  • The Purribean is yours to explore when Cat Quest III launches for Nintendo Switch on Aug. 8.
  • For the latest news and updates about indie games on Nintendo Switch, follow the Indie World X account @IndieWorldNA and check out https://www.nintendo.com/us/indie-world/news/ .
  • * Any Nintendo Switch Online membership (sold separately) and Nintendo Account required for online features.

PolyU researchers introduce biomineralisation as sustainable strategy against microbial corrosion in marine concrete

Retrieved on: 
Wednesday, April 10, 2024
Biomineralization, MIC, Hong Kong Polytechnic University, Polytechnic, Bacteria, Sewage, Hydrogen sulfide, Environmental Science & Technology, Research, Carbon footprint, Carbon, Corrosion, Ground substance, Environment, Biofilm, Faculty, SRB, Construction, Environmental science, Research institute, Urban, Lumber

In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.

Key Points: 
  • In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.
  • This biomineralisation strategy has strong potential for applications in corrosive environments, such as in marine and sewage settings, and water-cooling utilities, where concrete corrosion is induced by corrosive microorganisms.
  • A paper reporting the research, " Biomineralisation to prevent microbially induced corrosion on concrete for sustainable marine infrastructure ", has been published in Environmental Science & Technology.
  • The results contribute to the development of new techniques for inhibiting corrosion to achieve sustainable marine concrete structures.

PolyU researchers introduce biomineralisation as sustainable strategy against microbial corrosion in marine concrete

Retrieved on: 
Wednesday, April 10, 2024
Biomineralization, MIC, Hong Kong Polytechnic University, Polytechnic, Bacteria, Sewage, Hydrogen sulfide, Environmental Science & Technology, Research, Carbon footprint, Carbon, Corrosion, Ground substance, Environment, Biofilm, Faculty, SRB, Construction, Environmental science, Research institute, Urban, Lumber

In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.

Key Points: 
  • In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.
  • This biomineralisation strategy has strong potential for applications in corrosive environments, such as in marine and sewage settings, and water-cooling utilities, where concrete corrosion is induced by corrosive microorganisms.
  • A paper reporting the research, " Biomineralisation to prevent microbially induced corrosion on concrete for sustainable marine infrastructure ", has been published in Environmental Science & Technology.
  • The results contribute to the development of new techniques for inhibiting corrosion to achieve sustainable marine concrete structures.

Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute

Retrieved on: 
Tuesday, April 9, 2024
Psilocybin, First Nations, Wharerātā, Certificate, Patient, Ethics, FRA, COA, Synthetic, Health Canada, Trial of the century, GMP, Clinical trial, Ground substance, Safety, MDMA, Medsafe, Medicine, Pharmaceutical industry

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing of an international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute (Mātai), on behalf of the Tū Wairua Project.

Key Points: 
  • VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing of an international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute (Mātai), on behalf of the Tū Wairua Project.
  • This agreement marks Optimi's first supply deal to New Zealand, a significant milestone for the company's global expansion efforts.
  • Under the terms of the agreement, Optimi will provide Mātai with a quantity of its validated GMP Full Spectrum Natural Psilocybin extract.
  • Further, the agreement includes tracked stability of the extract, ensuring the highest standards of GMP quality and compliance.

Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract

Retrieved on: 
Tuesday, April 2, 2024
Psilocybin, Psilocybe, Organization, Documentation, Learning, Certificate, Patient, Research, Good manufacturing practice, FRA, COA, International Council, Health Canada, GMP, Data collection, Quality, Harmonization, Ground substance, GACP, Water, Safety, ICH, MDMA, Good

Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.

Key Points: 
  • Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.
  • The third-party COA confirms critical information regarding potency, water content, microbial content, and heavy metal content, ensuring that the Natural Psilocybin Extract meets the predetermined specifications.
  • The completion of both extract validation and finished product testing aligns with Optimi's goal of advancing the drug candidate, marking significant progress toward its eventual release for human consumption.
  • “Obtaining successful results on the validation batches of psilocybin extract speaks to Optimi’s dedication to developing a repeatable, quality focused manufacturing process.

Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

Retrieved on: 
Thursday, March 28, 2024
Tel Aviv University, EST, Conference, Research, Good manufacturing practice, FRA, Health Canada, GMP, Ground substance, Safety, API, Good, MDMA, Therapy, Psychedelic drug, Drug development, Pharmaceutical industry

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference.

Key Points: 
  • VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference.
  • The 4th Annual Psychedelic Therapeutics and Drug Development Conference convenes renowned researchers and esteemed leaders from academia, industry, non-profit organizations, and government sectors to explore the challenges and opportunities inherent in the research and development of psychedelic therapies for various health conditions with significant unmet needs.
  • “We believe this conference serves as an excellent platform for us to engage with key stakeholders, exchange ideas, and drive innovation in the field of psychedelic therapeutics,” he added.
  • Optimi delegates will be available at the conference to host networking sessions for those seeking more information about the company's GMP and API drug products.

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

Retrieved on: 
Tuesday, March 26, 2024
Tel Aviv University, Interdisciplinarity, Mental health, Research, FRA, Health Canada, Abstract, GMP, Quality, Ground substance, API, MDMA, Psychedelic drug, Pharmaceutical industry

In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.

Key Points: 
  • In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.
  • Optimi has received the import permit from IPR-TLV and is in the process of obtaining its export permit from Health Canada.
  • Expected to commence in the summer of 2024 and conclude in late 2025, this study aligns with Optimi's commitment to supplying MDMA to international researchers advancing mental health and addictions research.
  • Commenting on the collaboration, Optimi CEO Bill Ciprick expressed his enthusiasm, stating, "Our agreement with IPR-TLV signifies an exciting entry into the Israeli psychedelics research market for Optimi.